FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Merck Touts New Keytruda Endometrial Cancer Data

[ Price : $8.95]

Merck says it will meet with regulatory authorities about an expanded indication after reporting Phase 3 trial results of Keytruda...

House Committee Questions FDA Drug Shortage Actions

[ Price : $8.95]

The leadership of the House Energy and Commerce Committee and two of its subcommittees asks FDA for detailed drug shortage informa...

Guide on Contact Lens Submissions

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Soft (Hydrophilic) Daily Wear Contact Lenses Performance C...

Guide on Animal Studies for Devices

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled General Considerations for Animal Studies Intended to Evalu...

Cell, Gene Therapy Application Backlog Questioned

[ Price : $8.95]

The chair and ranking member of the House Energy and Commerce Health subcommittee ask CBER director Peter Marks for detailed infor...

Bipartisan Bill on Interchangeable Biologics

[ Price : $8.95]

Four U.S. Representatives introduce the Biologics Competition Act, a bipartisan bill that would order HHS to evaluate the process ...

GSK Will Seek Expanded Use for Jemperli

[ Price : $8.95]

GSK says it plans to submit a BLA supplement by 7/1 after reporting interim results from a Phase 3 trial investigating Jemperli (d...

Labeling Changes Approved for 2 Hedgehog Inhibitors

[ Price : $8.95]

FDA approves changes to labeling for two Hedgehog inhibitors covering musculoskeletal adverse reactions and creatine kinase monito...

Guide on Animal Studies for Devices

[ Price : $8.95]

FDA publishes a final guidance entitled General Considerations for Animal Studies Intended to Evaluate Medical Devices.

Under Protest, Brainstorm Resubmits BLA for NurOwn

[ Price : $8.95]

BrainStorm Cell Therapeutics says it has refiled a BLA under the agencys file-over-protest procedure for NurOwn, a stem cell thera...